A case of primary squamous cell carcinoma of the parotid gland and review of the literature

Jingli Zhao, Xinrong Nan, Chuhuan Zhou, Nan Jiang, Liangliang Tian

ABSTRACT

Introduction: Primary parotid squamous cell carcinoma (PPSCC) is a rare malignant epithelial tumor originating in the parotid gland with complex diagnostic procedures and a poor prognosis. The etiology, tissue origin, and biological behavior of the disease are currently unknown due to its underreporting. It is crucial to differentiate this type of squamous cell carcinoma (SCC) of the parotid gland from other salivary gland tumors because of its widespread invasiveness, which leads to high mortality.

Case Report: This article reports a case of a 62-year-old male patient in whom histopathological examination confirmed that the tumor was squamous cell carcinoma. Since the patient had no other main source, the ultimate diagnosis was the primary SCC of the parotid gland. The patient is currently receiving routine follow-up care and has shown no signs of recurrence.

Conclusion: In conclusion, even asymptomatic individuals should be highly regarded to prevent mistakes because the diagnostic process for this disease is complicated. The presence of metastatic cancer should be ruled out, and histology and immunohistochemistry should be used to confirm the diagnosis.

Keywords: Fine-needle aspiration cytology, Parotid gland, Parotid squamous cell carcinoma, Primary squamous cell carcinoma

INTRODUCTION

Primary parotid squamous cell carcinoma (PPSCC) is a rare and aggressive malignant tumor with highly malignant potential, older age of onset, and more complex diagnostic procedures. Additionally, the incidence is increasing, and even with surgery and adjuvant radiotherapy (ART), the prognosis is dismal [1]. True PPSCC is very rare and accounts for 0.1–3.4% of all parotid malignancies [2]. According to some researchers, PPSCC can be identified if high-grade mucoepidermoid carcinoma (MEC) and metastatic parotid squamous cell carcinoma (SCC) are ruled out [3]. However, there are very few reports in the literature on diagnosing and treating PPSCC. Additionally, the majority of publications only involve a small number of individuals, perhaps because this disease is uncommon. In this case, the patient changed the treatment plan intraoperatively to re-expand the resection because of the difficult diagnosis and variable pathologic returns, which lengthened the procedure and raised the surgical risk. Due to these factors, this paper aims to raise awareness of PPSCC by presenting a case study and a review of the relevant scientific literature.
CASE REPORT

A 62-year-old male patient presented with a painless mass in the left preauricular region for more than two months and was admitted with a left parotid tumor. There was no previous history of a mass in the same area or the neck. He had been treated at a local hospital before admission, and his diagnosis was unknown. On examination, the patient had a palpable mass in the left parotid gland, measuring about 3 cm by 2 cm by 2 cm, hard, inactive, adherent to the surrounding tissues, nontender, and without symptoms of facial paralysis. There were multiple enlarged lymph nodes in the neck.

An enhanced computed tomography (CT) examination was performed after admission, and there was a soft tissue shadow next to the left masseter muscle, involving the masseter muscle and the left parotid gland, considering the possibility of a malignant occupational lesion of salivary gland origin. Enhanced MRI showed abnormal signals in the left masseter muscle and the left parotid gland, and an infectious lesion with abscess formation was considered possible. The patient also underwent fine-needle aspiration cytology (FNAC), and the puncture fluid was sent for pathologic examination. The pathology report showed that the tissue sent for examination showed more inflammatory cell infiltration and multinucleated cell aggregation, and small foci of moderate heterogeneous epithelial hyperplasia were seen. Immunohistochemical results: CK (+), CK7 (−), p40 (+), p63 (+), p53 (mutant+). Special staining results: AB/PAS (−). The patient was admitted to the hospital for an infusion and anti-inflammatory treatment, and the self-conscious swelling became smaller. Preliminary Diagnosis: Consider lymphadenitis first, tumor second, and nature to be investigated.

On the 15th day after the patient was admitted to the hospital, “resection of parotid tumor” was performed under general anesthesia. The tumor was located on the deep lobe of the parotid gland, with no peripheral membrane, an unclear boundary, a hard texture, poor mobility, and the marginal mandibular branch of the facial nerve (FN) tightly adherent to the tumor. Partial excision of tumor tissue was sent intraoperatively for frozen pathology return (left parotid mass): consider inflammatory lesions. A “resection of parotid tumor + dissection of the FN” was performed, and after the tumor was removed, a second frozen pathology report was sent (left parotid mass): moderately differentiated SCC. “Extended resection of parotid malignant tumor + supraglottic lymphadenectomy” was performed. Intraoperative frozen (left parotid lymph node) was sent: no cancer metastasis was seen. Postoperative pathological findings: moderately differentiated SCC with no cancer metastasis in the lymph nodes. Immunohistochemical results: CK (+), CK7 (−), p40 (+), p63 (+), p53 (mutant+), and Ki67 (40%+).

In this case, the patient received the recommendation for postoperative ART, but it was postponed for personal reasons. There are no signs of recurrence and long-term follow-up needs to be further observed.

DISCUSSION

Primary parotid squamous cell carcinoma is a malignant tumor that is uncommon, aggressive, and has a very negative prognosis. Squamous cell carcinoma makes up between 9% and 17% of parotid adenocarcinomas and between 0.1% and 3.4% of all parotid tumors [4]. The disease typically affects elderly people and has a brief duration and rapid progression. In most patients, the disease manifests as a painless neck mass, an infiltrative growth that is hard and adheres to surrounding tissues. It is simple to misdiagnose a patient’s illness, delaying treatment [5]. Our patient was 62 years old, had a smooth skin surface without any erosions or breakouts, and did not exhibit any symptoms like facial paralysis or pain. He had been seen by a local hospital without receiving a definitive diagnosis, and when he came to our hospital, he complained of a tumor that had shrunk. This led to the first diagnosis of lymphadenitis.

Primary parotid squamous cell carcinoma is rare and typically results from the metastasis of an extranodal original tumor. Right now, the diagnosis is one of exclusion. If the patient has a history of SCC of the head and neck, other distant sites, or contemporaneous SCC, salivary gland involvement is regarded as metastatic. When paired with a thorough clinical history and improved cross-sectional imaging, it is typically able to tell the difference between primary and metastatic parotid gland SCC [1, 2].

Magnetic resonance imaging should be the imaging method of the first choice. It is efficient in verifying suspected malignancy and can provide extensive anatomical information regarding the primary tumor’s location and its relationship to the FN and surrounding tissues [3, 4]. In addition to the well-known signs of parotid malignancy, such as poorly defined borders, large tumor size with noticeable invasiveness, irregular shape, infiltration of extra-parotid lymph nodes, and low to moderate signal intensity on T2-weighted images, relatively large tumors with central necrosis is a useful imaging feature of SCC originating in the parotid gland (Figure 1) [5, 6].

Furthermore, to accurately diagnose PPSCC, metastatic SCC of the parotid gland and high-grade MEC must be excluded [7]. High-grade MEC with a predominantly squamous component is very difficult to distinguish from SCC of the parotid gland with the aid of histopathologic examination, in contrast to SCC of the parotid gland, where low-grade and intermediate-grade MEC rarely cause diagnostic confusion. Also, MEC stain positive for intracellular mucin with PAS or mucicarmine stains which are absent in parotid SCC [8]. Almost all reported PPSCCs have been categorized as moderately highly differentiated and exhibit all the traditional.
histologic characteristics, as stated by Batsakis et al. for the creation of intracellular bridges, intracellular keratinization, keratin pearls, and a lack of mucin synthesis (Figure 2) [9].

In order to obtain a reliable histologic diagnosis, Mezi et al. [3] recommended a FNAC before surgery. Fine-needle aspiration cytology is widely used in the preoperative adjunctive diagnosis of head and neck tumors, but its diagnostic value for salivary gland tumors is controversial. It has been shown that the ability of FNA to differentiate between benign lesions and malignant tumors for all samples is 83%, for benign tumors 89%, and for malignant tumors 59% [10]. Therefore, FNA is more accurate in the diagnosis of benign parotid tumors. The accuracy of FNA depends on the quality of the sample material and the pathologist’s experience in evaluating it [11]. In this case, the result was false negative, with more inflammatory cell infiltration and multinucleated cell aggregates seen in the perforated tissue, and small foci of moderate anisotropic epithelial hyperplasia (Figure 3). False negatives may be the result of the needle localizing outside the target cells and failing to aspirate tissue from the lesion, necrosis within the tumor, hemorrhage, penetration into areas of cystic degeneration, or poor quality push slides [11, 12]. It can be highly helpful to the operator in developing a treatment plan as a first line of defense for the diagnosis of parotid malignancy, but some surgeons are less confident due to its relatively low sensitivity, false-negative, and false-positive outcomes [13, 14]. While intraoperative frozen sections are extremely reliable for detecting PPSCC, they are also crucial for excluding malignancy when the results of an FNAB are in doubt [15]. A basis for a clear intraoperative treatment plan is provided. Additionally, as PPSCC typically lacks any mucous cells, the application of specific stains (such as PAS reaction, Astra, or Alzian blue) is a useful supplementary diagnostic approach to distinguish MEC [8, 16].

Figure 1: A 62-year-old male with primary parotid squamous cell carcinoma in the left parotid gland. Magnetic resonance images were acquired using a 3.0 T MRI machine. Axial T2WI (A) and T1WI (B) show an irregular mass involving the left parotid gland and masseter muscle, with the tumor showing a slightly low signal and multiple small focal areas of markedly high signal on T2WI (arrow). Enhanced axial (C) and coronal (D) T1WI show inhomogeneous enhancement with necrotic areas in the center (arrow).

Figure 2: Photomicrograph of the fine-needle aspiration cytology. The cells were heteromorphic, the mitosis was obvious, the ratio of nucleus to plasma was increased, and keratinized beads were formed.

Figure 3: More inflammatory cell infiltration and multinucleated cell aggregates were seen in the tissues, as well as small foci of moderate anisotropic epithelial hyperplasia.
The patient in our situation was a 62-year-old male. No other primary lesions were discovered during the preoperative clinical examination, enhanced CT of the head, neck, and chest, or enhanced MRI, and metastatic SCCs of the parotid gland were ruled out. In order to exclude high-grade MEC, the pathologic diagnosis of PAS (−) was used to corroborate the diagnosis of primary SCC of the parotid gland.

The aggressive nature of parotid SCC necessitates multimodal therapy, which includes surgical resection, neck surgery, adjuvant radiation, and/or chemotherapy [1]. The extent of initial surgery is critical to the success of treatment. Superficial parotidectomy combined with dissection of the FN is the recommended minimum extent of resection for primary SCC [17]. According to Xiao [18], total parotidectomy is advised for patients who have primary or recurring SCC of the parotid gland. It is advised to leave the FN intact after parotidectomy if it has not been invaded. It is advised to remove the infiltrated facial nerve and its branches during parotidectomy if the FN is affected. Previous studies have advised standard elective cervical dissection in all patients with primary parotid carcinoma and clinically negative necks for cervical lymph nodes. For patients of primary or recurrent parotid SCC at stage cN0, selective cervical lymph node dissection is advised, while radical cervical lymph node dissection is advised for cases at stage cN1 + [17–19]. Furthermore, Lee et al. [20] concluded that postoperative radiation is thought to be necessary due to its most typical form of failure, localized regional recurrence. Within six weeks of surgery, Xiao [18] highly advise adjuvant radiation to the ipsilateral neck and parotid bed. 60–70 Gy should be the dose. The surgical bed should be included in the radiation field, along with the ipsilateral neck and parotid bed. Additionally, Mezi et al. [3] came to the conclusion that a standard dose of 100 mg/mq of cisplatin combined with radiochemotherapy should be given every three weeks to young patients with parotid SCC who have a good physical status score (PS) in order to lower the high risk of progression after surgical treatment.

While Xiao [18] believe that chemotherapy/targeted therapy is only recommended for advanced and/or recurrent cases. For advanced and unresectable cases, chemotherapy/targeted therapy is only recommended as a palliative treatment, especially for those cases where surgery is not indicated. Finally, integration of nearby tissue and reconstruction to heal the tissue defect may be considered in cases with substantial resection of parotid SCC. For the repair of skin or mucosal abnormalities in the parotid region, adjacent flaps (Z-flap, gliding flap, or rhombic flap) are advised; anterolateral thigh flap (ALTFL) or pectoralis major myocutaneous flap (PMMF) are suggested as alternatives. Reconstruction is only advised for muscle or bone abnormalities when there are negative margins.

Squamous cell carcinomas of the parotid gland have a poor prognosis, with a median patient survival of just 13–24 months and a previously reported five-year survival at around 50%. Additionally, even with surgery and ART, the prognosis is poor and the prevalence is rising [17, 18, 20, 21]. Black race, age 75 and older, tumor T3 and above, and high clinical stage were found to be significant predictors of poor prognosis in the study by Pfisterrell et al. [22]. Adjuvant radiation considerably decreased locoregional recurrence in patients overall, but it had no appreciable impact on survival rates [23]. The inclusion of chemotherapy to adjuvant therapy in patients with advanced salivary gland SCC may increase patients’ long-term survival [24].

In this case, after the intraoperative frozen pathology results were reported, the patient underwent “extended resection of parotid malignant tumor + dissection of the FN + supraglottic lymphadenectomy,” and in order to minimize recurrence, the patient is advised to undergo ART one month after the operation. The patient currently exhibits clear indicators of facial paralysis of the left lower lip and the elimination of the left frontal line without any indications of recurrence, but further research is needed to determine the long-term therapeutic benefit.

CONCLUSION

In conclusion, even asymptomatic individuals should be highly regarded to prevent mistakes because the diagnostic process for this disease is complicated and clinical features are crucial for the diagnosis. The presence of metastatic cancer should be ruled out, and histology and immunohistochemistry should be used to confirm the diagnosis. Patients should be taken into account for “extended resection of malignant tumors” and “selective neck dissection.” The preservation of the FN may be an option for patients whose tumors do not affect the FN, but this treatment carries a high risk of recurrence and distant metastases, and the prognosis is dismal, thus all patients should get postoperative adjuvant therapy. Therefore, postoperative adjuvant therapy ought to be given to all patients. This condition necessitates lifetime monitoring of patients.

REFERENCES


Author Contributions
Jingli Zhao – Conception of the work, Design of the work, Acquisition of data, Analysis of data, Interpretation of data, Drafting the work, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved
Xinrong Nan – Design of the work, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved
Chuhuan Zhou – Acquisition of data, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved
Nan Jiang – Analysis of data, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved
Liangliang Tian – Interpretation of data, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved

Guarantor of Submission
The corresponding author is the guarantor of submission.
Source of Support
None.

Consent Statement
Written informed consent was obtained from the patient for publication of this article.

Conflict of Interest
Authors declare no conflict of interest.

Data Availability
All relevant data are within the paper and its Supporting Information files.

Copyright
© 2024 Jingli Zhao et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.
Submit your manuscripts at
www.edoriumjournals.com